Back to Directory

Justine Beck

Email

Justine.beck@nih.gov

Phone

301-761-5288

Institution

PAB, DAIDS, NIAID, NIH

Address

Pharmaceutical Affairs Branch
5601 Fishers Lane
MSC 9829
Rockville, MD 20852

Request an Update

Affiliated Studies

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

Research Area

Study Status

Closed to Follow Up

IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV

DAIDS Number

Research Area

Cure and Immunotherapy

IMPAACT 2042: Tatelo Plus

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

IMPAACT 2039: EXCEED

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

Research Area

Study Status

Show All